Italian Patients Receive Samsara Vision’s SING IMT, a New Technology for AMD

Italian Patients Receive Samsara Vision’s SING IMT, a New Technology for AMD

February 23, 2022

Samsara Vision announced the first three successful clinical cases in Italy using its SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope) for people living with late-stage, age-related macular degeneration (AMD).

The SING IMT was successfully implanted in patients in early February by Professor Stanislao Rizzo, director of the Ophthalmology Unit of the Agostino Gemelli IRCCS University Polyclinic Foundation and Ordinary of Ophthalmology Clinic at the Catholic University campus in Rome.

The SING IMT is a Galilean telescope implant that is nearly invisible inside the eye and is aimed to improve visual acuity and quality of life for people with late-stage AMD.

The SING IMT, which is made up of ultra-precise micro-optics, is implanted during routine outpatient cataract surgery.

Patients work closely with a low vision specialist and occupational therapists after surgery to learn how to use their new vision, often practicing with exercises designed to their unique vision objectives.

Imagery in "straight-ahead" vision is magnified 2.7 times and projected onto healthy, undamaged parts of the macula in the back of the eye, decreasing the impact of the AMD "blind spot" in central vision and allowing patients to see previously unrecognizable images.

“It is incredibly exciting to introduce the SING IMT as a treatment option to patients in Italy whose vision has been severely compromised by late-stage AMD. Macular degeneration not only robs people of their vision, but of their independence as they have to rely on others to read to them or describe what is right in front of them. It can be isolating,” Professor Rizzo said in a company news release.

“It’s a privilege to offer my patients high quality care and access to the most advanced treatment options. I’m hopeful that these first three patients are just the first of many who will experience improved vision and then reconnect to the people and activities that they enjoy.”

The SING IMT is approved for late-stage AMD patients who are 55 years of age or older in CE Referenced Countries and is not currently FDA approved in the United States.

To learn more about SING IMT, visit